• Wed, March 1, 2023

Vikram Purohit Maintained (ARQT) at Buy with Decreased Target to $50 on, Mar 1st, 2023

Vikram Purohit of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Decreased Target from $51 to $50 on, Mar 1st, 2023.

Vikram, nor any peers, have made any analyst calls on ARQT in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30

Like: 👍